Science-Driven. Patient-Centered.
Operating across 12 global research centers, Zenth Pharma invests over $4.2B annually in biomedical research, maintaining a pipeline of 80+ novel therapeutics and 18 approved molecular entities.
Oncology
Next-generation targeted therapies, CAR-T cell engineering, and tumor microenvironment modulators for solid and hematologic malignancies.
Rare Diseases
Orphan drug development focused on orphan genetic disorders, lysosomal storage diseases, and metabolic deficiencies with high unmet medical need.
Neurology
Blood-brain barrier penetrating platforms, neuroinflammation modulators, and disease-modifying therapies for Alzheimer's, Parkinson's, and ALS.
Immunology & Autoimmunity
Selective cytokine inhibitors, biologics for chronic inflammatory conditions, and microbiome-targeted immunomodulators.
Infectious Diseases
Broad-spectrum antivirals, novel antibiotic classes targeting resistant pathogens, and rapid-deployment vaccine platforms.
AI & Computational Discovery
Proprietary deep learning models for protein folding, target identification, and de novo molecular design reducing discovery timelines by 60%.
Clinical & Preclinical Programs
Tracking our advanced molecular entities from discovery through FDA/EMA approval pathways.
| Program Code | Therapeutic Area | Mechanism | Approval Regions | Status |
|---|---|---|---|---|
| ZP-401 | Oncology (SCLC) | PARP/ATR Dual Inhibitor | US, EU, JP | Approved 2024 |
| ZP-512 | Rare Disease (Pompe) | Gene Augmentation (AAV) | US, EU | Approved 2023 |
| ZP-608 | Immunology (RA) | Selective JAK3 Inhibitor | Global | Approved 2022 | d>
| Program Code | Indication | Mechanism | Partners | Status |
|---|---|---|---|---|
| ZP-729 | Metastatic Pancreatic CA | Next-Gen CAR-NK | NCT05881203 | Phase III |
| ZP-814 | Early Alzheimer's | Tau-Targeting mAb | NCT05990112 | Phase III |
| ZP-880 | Chronic Hepatitis B | RNAi + Therapeutic Vaccine | NCT06102244 | Phase III |
| Program Code | Indication | Mechanism | Readout ETA | Status |
|---|---|---|---|---|
| ZP-901 | SARSCoV-2 Variant Shield | Pan-Spike Nanobody Cocktail | Q4 2025 | Phase II |
| ZP-915 | Multiple Sclerosis | BBB-Permeable S1P Modulator | Q2 2026 | Phase II |
| Program Code | Target | Modality | Discovery Lead | Status |
|---|---|---|---|---|
| ZP-1042 | KRAS G12C/D | Covalent Small Molecule | Computational AI Platform | Phase I |
| ZP-1088 | IL-23/IL-17 Axis | Bispecific Antibody | Cambridge Biologics Center | Phase I |
Centers of Excellence
Purpose-built laboratories, GMP manufacturing suites, and clinical trial coordination hubs across four continents.
Regulatory & Ethical Standards
Every program adheres to rigorous international standards, ensuring patient safety, data integrity, and transparent development.
FDA / EMA / PMDA Aligned
All trials follow ICH-GCP guidelines with continuous regulatory agency feedback integration.
cGMP Manufacturing
WHO-certified facilities operating under strict quality control, batch release protocols, and audit readiness.
Ethical AI Governance
Transparent algorithmic auditing, bias mitigation frameworks, and human-in-the-loop validation for computational discovery.
Data Integrity & Privacy
HIPAA/GDPR-compliant clinical data management with end-to-end encryption and decentralized trial platforms.
Collaborate with Zenth Pharma
Explore co-development partnerships, investigator-initiated trials, or clinical site opportunities.